**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event\* Drug interaction

In a study of 1039 patients hospitalised for COVID-19 pneumonia in Italy from 12 February to 15 March 2020, 12 patients including 8 men and 4 women aged 69−89 years were described who developed increased plasma level of anticoagulants following drug-drug interaction between apixaban, dabigatran etexilate, edoxaban or rivaroxaban, and darunavir/ritonavir or lopinavir/ritonavir. All patients received off label treatment antivirals for COVID-19 pneumonia \[*not all routes and dosages stated; duration of treatment to reaction onset and outcome not stated*\].

The patients were hospitalised due to COVID-19 pneumonia for treatment. All patient had been receiving daily does of direct oral anticoagulants (DOAC) included dabigatran etexilate 110 mg (n=1), apixaban 2.5 mg (n=1) and 5 mg (n=4), edoxaban 30 mg (n=2 and 60 mg (n=1) and rivaroxaban 15 mg (n=2) and 20 mg (n=1) for non-valvular atrial fibrillation (n=11) and treatment and prevention of venous thromboembolism (n=1). Prior to admission, a plasma trough concentration for DOAC ranged as follows (ng/mL): apixaban 71−112, edoxaban 11−102, rivaroxaban 12−16 and dabigatran etexilate 54. On admission, the patient started receiving off-label treatment with lopinavir/ritonavir (n=8) and darunavir/ritonavir (n=4) while continuing DOAC. Additionally, they all received off label treatment with hydroxychloroquine and unspecified antibacterial. After treatment initiation, plasma samples were collected. During admission, the plasma trough concentrations of DAOC were as follows (ng/mL): apixaban 142−420, edoxaban 71−473, rivaroxaban 99−505 and dabigatran etexilate 221. This increase in DAOC plasma levels was a result of drug interaction of lopinavir/ritonavir (n=8) and darunavir/ritonavir (n=4) with DOAC.
